See more : Amaru, Inc. (AMRU) Income Statement Analysis – Financial Results
Complete financial analysis of Royalty Pharma plc (RPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Royalty Pharma plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- American Shared Hospital Services (AMS) Income Statement Analysis – Financial Results
- Inventis Limited (IVT.AX) Income Statement Analysis – Financial Results
- H2O Innovation Inc. (HEO.TO) Income Statement Analysis – Financial Results
- InflaRx N.V. (IF0.DE) Income Statement Analysis – Financial Results
- Gold Digger Resources Inc. (GDIG.CN) Income Statement Analysis – Financial Results
Royalty Pharma plc (RPRX)
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B | 1.65B |
| Cost of Revenue | 560.66M | 5.67M | 23.00M | 88.11M | 1.02B | 135.96M | 33.27M | 0.00 | 0.00 |
| Gross Profit | 1.79B | 2.23B | 2.27B | 2.03B | 794.93M | 1.66B | 1.56B | 1.88B | 1.65B |
| Gross Profit Ratio | 76.19% | 99.75% | 99.00% | 95.85% | 43.82% | 92.43% | 97.92% | 100.00% | 100.00% |
| Research & Development | 52.00M | 177.11M | 200.08M | 26.00M | 83.04M | 392.61M | 117.87M | 91.02M | 98.38M |
| General & Administrative | 249.75M | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M | 106.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 249.75M | 227.30M | 182.83M | 182.00M | 103.44M | 61.91M | 106.44M | 69.51M | 121.42M |
| Other Expenses | 560.66M | 909.91M | 475.84M | 319.00M | -995.40M | -1.52M | -1.62M | -925.80M | -570.18M |
| Operating Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.09B | 789.98M |
| Cost & Expenses | 862.40M | 1.31B | 858.75M | 527.00M | -808.92M | 430.45M | 658.24M | 1.15B | 858.14M |
| Interest Income | 72.29M | 78.34M | 53.54M | 28.38M | 22.33M | 24.44M | 6.76M | 0.00 | 0.00 |
| Interest Expense | 187.19M | 187.96M | 166.14M | 157.00M | 268.57M | 279.96M | 247.34M | 238.92M | 224.42M |
| Depreciation & Amortization | 395.13M | 5.67M | 23.00M | 23.06M | 23.92M | 33.27M | 33.27M | 68.20M | 68.16M |
| EBITDA | 1.89B | 928.56M | 1.45B | 1.68B | 2.65B | 1.40B | 972.96M | 1.07B | 862.44M |
| EBITDA Ratio | 80.15% | 43.95% | 64.73% | 88.69% | 145.37% | 78.76% | 71.46% | 42.14% | 52.19% |
| Operating Income | 1.49B | 977.50M | 1.43B | 1.60B | 2.62B | 1.36B | 939.69M | 722.87M | 794.28M |
| Operating Income Ratio | 63.37% | 43.69% | 62.49% | 75.16% | 144.59% | 76.02% | 58.81% | 38.50% | 48.07% |
| Total Other Income/Expenses | 207.94M | -77.00M | -189.51M | 106.56M | -161.76M | 153.41M | 403.49M | 39.02M | -35.57M |
| Income Before Tax | 1.70B | 230.06M | 1.24B | 1.70B | 2.46B | 1.52B | 1.34B | 761.90M | 758.71M |
| Income Before Tax Ratio | 72.20% | 10.28% | 54.21% | 80.21% | 135.67% | 84.57% | 84.06% | 40.58% | 45.91% |
| Income Tax Expense | 0.00 | 187.23M | 762.45M | 1.15B | 349.33M | 433.37M | 542.66M | 195.99M | 177.28M |
| Net Income | 1.13B | 42.83M | 478.75M | 495.20M | 2.35B | 1.38B | 1.21B | 565.91M | 581.43M |
| Net Income Ratio | 48.20% | 1.91% | 20.91% | 23.34% | 129.45% | 76.76% | 75.72% | 30.14% | 35.19% |
| EPS | 3.41 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| EPS Diluted | 2.53 | 0.10 | 1.15 | 1.32 | 6.42 | 3.89 | 3.42 | 0.93 | 0.96 |
| Weighted Avg Shares Out | 447.60M | 437.96M | 414.79M | 375.44M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
| Weighted Avg Shares Out (Dil) | 602.90M | 437.97M | 414.80M | 375.46M | 365.90M | 354.18M | 354.18M | 607.04M | 607.04M |
7 Dividend Stocks to Buy at a 52-Week Low
On the search for high-quality stocks at low prices? Consider taking a look at dividend stocks at a 52-week low.
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Royalty Pharma PLC (RPRX) Q1 2024 Earnings Call Transcript
Royalty Pharma PLC (NASDAQ:RPRX ) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants George Grofik - Senior Vice President & Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman & Chief Executive Officer...
Royalty Pharma (RPRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Royalty Pharma (RPRX) Beats Q1 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago.
Royalty Pharma to Acquire Royalty Interest in Sanofi's Frexalimab
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for approximately $525 million in cash including estimated transaction costs. ImmuNext,...
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Insights Into Royalty Pharma (RPRX) Q1: Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Royalty Pharma (RPRX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host...
Source: https://incomestatements.info
Category: Stock Reports